Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY:
Mipomersen is a new agent to lower LDL-c in patients at increased risk of cardiovascular disease and/or intolerant to statins. Whereas safety concerns have focused on hepatic fat accumulation, to date no evidence of clinically relevant increases of intrahepatic triglyceride content are reported. Ongoing and future studies are eagerly awaited to assess the impact of mipomersen on hepatic triglyceride content after prolonged exposure.
|
Authors | Maartje E Visser, John J P Kastelein, Erik S G Stroes |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 21
Issue 4
Pg. 319-23
(Aug 2010)
ISSN: 1473-6535 [Electronic] England |
PMID | 20508521
(Publication Type: Journal Article, Review)
|
Chemical References |
- Apolipoproteins B
- Oligonucleotides
- mipomersen
|
Topics |
- Animals
- Apolipoproteins B
(biosynthesis, metabolism)
- Clinical Trials as Topic
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Oligonucleotides
(adverse effects, pharmacology)
- Protein Biosynthesis
(drug effects)
|